ページ 1 から 80 結果
This cross-sectional survey was initiated and conducted by the French Society of Geriatrics and Gerontology. A standardized questionnaire was emailed to 1600 geriatrician members of the French Society of Geriatrics and Gerontology throughout France between March 22, 2020 and April 5, 2020.
Pancreatic cancer is a rapidly developing cancer with a poor prognosis. 5-year survival is 6% in Europe and the USA. The FOLFIRINOX protocol has become the standard medical treatment for this pathology. However, FOLFIRINOX is the cause of severe toxicities dominated by leuko-neutropenia,
Introduction Breast cancer is the most common tumour type in women worldwide. The success of the treatment of breast cancer have improved hence the prevalence of survivors have increased (American Cancer Society). However, experienced side effects from the cancer itself or from cancer treatments is
INTRODUCTION & STATE-OF-ART Cystic Fibrosis (CF) is the most common autosomal recessive lethal disorders affecting 1 in 2.500 newborns among Caucasians. CF lung disease reflects a failure in the capacity of airway epithelia to normally hydrate their surface. Poor hydration of airways surfaces leads
Randomized, open-label, parallel-group, multicenter, phase III trial with two arms, one with acalabrutinib (Arm A) and the other with the standard of care for the management of early Binet stage A patients "clinical observation (watch & wait)" (Arm B) in patients with untreated early stage CLL and
Hemolytic uremic syndrome (HUS) is a form of thrombotic microangiopathy, characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute renal impairment of varying severity, which may be preceded by an episode of diarrhea with or without blood. Karmali et al. showed the relationship
PHASE I DESIGN
The number of evaluable patients to be included in this trial is 25. However 28 patients will be enrolled considering the possibility of 3 non-evaluable cases.
The dose escalation rules proceed as follows: escalating in cohorts of 3-6 patients per dose level. Three patients are
The combination of Oxaliplatin and Gemcitabine has synergistic effects on a variety of human cancer cell lines in vitro. Clinically, it has demonstrated activity in other malignancies including lung, and pancreas. In the former study, poor prognosis advanced non-small cell lung cancer patients
Biliary tract cancer (BTC) is a common term for malignant tumors that occur in gallbladder and bile duct, the path in which bile is released. According to the anatomical location, biliary tract cancer is divided into intrahepatic cholangiocarcinoma and extrahepatic
PRIMARY OBJECTIVES:
I. To estimate the safety and tolerability (adverse event rate) of the combination of palbociclib and letrozole or fulvestrant in adults age 70 or older with estrogen receptor-positive, HER2-negative metastatic breast cancer.
SECONDARY OBJECTIVES:
I. To describe the full toxicity
Rationale and Background:
Dual antiplatelet therapy with Aspirin and Clopidogrel represents the standard of care for the prevention of recurrent ischemic events in patients undergoing percutaneous coronary intervention (PCI). For more than 10 years, dual antiplatelet therapy with Aspirin and
OBJECTIVE Nonalcoholic fatty liver disease (NAFLD) is a public health problem in patients with type 2 diabetes mellitus (T2DM). The presence of type 2 diabetes in patients with NAFLD is a risk factor for its progression to a more severe liver disease known as nonalcoholic steatohepatitis (NASH).
The analgesic efficacy of ultrasound guided continuous quadratus lumborum block versus continuous paravertebral block in radical cystectomy
Protocol of a thesis submitted to the Faculty of Medicine University of Alexandria In partial fulfillment of the requirements of the degree of Master of
Acute disseminated encephalomyelitis can occur at any age, but usually affects children and young adults. The mean age of clinical presentation in pediatric cohorts ranges from 5 to 8 years. The annual incidence of Acute disseminated encephalomyelitis is reported to be 0.4-0.8 per 100,000 and the
The goal of personalized medicine is to tailor therapies to an individual patient with a goal of maximizing benefit and minimizing treatment related side effects. Inter-individual variability in metabolic enzymes can have a significant impact on cancer therapies. Pharmacogenomics (PGx) studies the